Vinci S.A. Stock
Price
Target price
€128.90
€128.90
1.020%
1.3
1.020%
€140.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Vinci S.A. Stock
Vinci S.A. gained 1.020% today.
Our community is currently high on Vinci S.A. with 4 Buy predictions and 0 Sell predictions.
With a target price of 140 € there is a slightly positive potential of 8.61% for Vinci S.A. compared to the current price of 128.9 €.
Pros and Cons of Vinci S.A. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vinci S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vinci S.A. | 1.020% | 0.989% | -9.600% | 7.589% | 6.156% | 21.086% | 44.311% |
| Bouygues S.A. | 2.320% | -1.757% | -7.227% | 32.022% | 9.572% | 56.532% | 41.219% |
| Eiffage S.A. Inh. | 2.260% | -1.645% | -11.680% | 17.558% | 5.846% | 32.580% | 47.827% |
| Trimble Navigation | 0.810% | -5.142% | -3.499% | -10.138% | -19.659% | 16.084% | -16.000% |
Comments
News
Is Intuitive Surgical a Buy Right Now?
Intuitive Surgical (NASDAQ: ISRG) has faced significant challenges over the past year, especially related to tariffs. The company's shares have lagged broader equities as a result, and with the
2 Stocks That Could Create Lasting Generational Wealth
Some of the most successful investors understand that the power of equity markets lies in their ability to generate consistent returns over the long run. While most traders lose money, people who
Intuitive Surgical Stock: Buy, Sell, or Hold?
Intuitive Surgical (NASDAQ: ISRG) reported exceptional fourth-quarter and full-year 2025 results earlier this year. Revenue and procedure volumes grew at robust double-digit rates as the company